Porton Pharma Solutions Ltd.

SZSE:300363 Stock Report

Market Cap: CN¥8.2b

Porton Pharma Solutions Dividends and Buybacks

Dividend criteria checks 0/6

Porton Pharma Solutions does not currently pay a dividend.

Key information

0%

Dividend yield

0.2%

Buyback Yield

Total Shareholder Yield0.2%
Future Dividend Yield0%
Dividend Growth33.1%
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ratio0%

Recent dividend and buyback updates

Recent updates

Pinning Down Porton Pharma Solutions Ltd.'s (SZSE:300363) P/S Is Difficult Right Now

Mar 19
Pinning Down Porton Pharma Solutions Ltd.'s (SZSE:300363) P/S Is Difficult Right Now

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jan 01
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Nov 14
Revenues Not Telling The Story For Porton Pharma Solutions Ltd. (SZSE:300363) After Shares Rise 31%

Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Sep 30
Porton Pharma Solutions Ltd.'s (SZSE:300363) 39% Price Boost Is Out Of Tune With Revenues

Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Sep 25
Porton Pharma Solutions (SZSE:300363) Has Debt But No Earnings; Should You Worry?

Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Jun 26
Is Porton Pharma Solutions (SZSE:300363) Weighed On By Its Debt Load?

Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

May 02
Analysts Just Shaved Their Porton Pharma Solutions Ltd. (SZSE:300363) Forecasts Dramatically

Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Mar 26
Does Porton Pharma Solutions (SZSE:300363) Have A Healthy Balance Sheet?

Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Mar 04
Porton Pharma Solutions Ltd.'s (SZSE:300363) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if 300363's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 300363's dividend payments have been increasing.


Dividend Yield vs Market

Porton Pharma Solutions Dividend Yield vs Market
How does 300363 dividend yield compare to the market?
SegmentDividend Yield
Company (300363)0%
Market Bottom 25% (CN)0.5%
Market Top 25% (CN)2.2%
Industry Average (Pharmaceuticals)1.7%
Analyst forecast (300363) (up to 3 years)0%

Notable Dividend: Unable to evaluate 300363's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 300363's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Earnings Payout to Shareholders

Earnings Coverage: 300363 is not paying a notable dividend for the CN market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 300363 has not reported any payouts.


Discover strong dividend paying companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/16 12:06
End of Day Share Price 2025/05/16 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Porton Pharma Solutions Ltd. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jin ZhangChina International Capital Corporation Limited
Zhu ChenCitic Securities Co., Ltd.
Kai WangCitic Securities Co., Ltd.